article thumbnail

In 2022, Donor Governments Spent US$8.2 billion on Efforts to Fight HIV/AIDS Globally, Returning to 2020 Funding Levels and Still Below the High-water Mark of Almost a Decade Ago

KFF

A new report from KFF and The Joint United Nations Programme on HIV/AIDS (UNAIDS) reveals that donor governments disbursed US$8.2 billion in 2014. billion in 2022 to combat HIV in low- and middle-income countries, returning to 2020 funding levels and still below the high-water mark of $8.6

article thumbnail

False Claims Act: Prediction on Supreme Court Ruling on Government Dismissal Authority

Healthcare Law Today

The case asks whether the government has authority to dismiss an FCA suit after initially declining to proceed with the action, and if so, what standard would apply. The Petitioner-Relator filed an FCA case against EHR on July 26, 2012 which the government investigated for about two years before declining to intervene on June 27, 2014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exploring Cigna's $172 Million Medicare Advantage Settlement

Healthicity

Specifically, the government alleged that Cigna submitted and failed to withdraw inaccurate and untruthful diagnosis codes in order to increase its payments from Medicare. government joined the action. Allegations Against Cigna Group A whistleblower initially brought forward the allegations and the U.S.

article thumbnail

NextGen to Pay $31M Settlement for False Claims Act Allegations

HIT Consultant

FCA Allegations The allegations contends that NextGen falsely obtained certification for its software in connection with the 2014 Edition certification criteria published by HHS’s Office of the National Coordinator.

article thumbnail

Using Legal Preparedness to Minimize Liability Barriers to Accessing Pandemic Vaccine and Medical Countermeasures

Bill of Health

Widespread international health emergencies, and particularly pandemics, can lead to a major imbalance of negotiating power between manufacturers and governments. Governments may face difficult policy decisions in their attempts to expeditiously control the spread of disease. Government, the U.S.

COVID-19 201
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

The selections feature topics ranging from a discussion of potential pathways to enable government patent use before nonpatent exclusivities expire, to an examination of medical oncologists who receive more than $100,000 annually from pharmaceutical companies, to an analysis of the launch prices of new drugs from 2008-2021. JAMA Intern Med.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

The selections feature topics ranging from an analysis of government and industry investments for recently approved drugs, to a discussion of court decisions on mifepristone, and an examination of the added therapeutic benefit associated with the top-selling brand-name drugs in Medicare. JAMA Netw Open. 2023 Apr 3;6(4):e238835.